Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus.
Yantong ZhuXuebing FengPublished in: Stem cell research & therapy (2018)
Allogeneic mesenchymal stem cell (MSC) transplantation has recently become a promising therapy for patients with systemic lupus erythematosus (SLE). MSCs are a kind of multipotent stem cell than can efficiently modulate both innate and adaptive immune responses, yet those from SLE patients themselves fail to maintain the balance of immune cells, which is partly due to the abnormal genetic background. Clarifying genetic factors associated with MSC dysfunction may be helpful to delineate SLE pathogenesis and provide new therapeutic targets. In this review, the scientific evidence on the genetic contribution to MSC dysfunction in SLE is summarized.
Keyphrases
- systemic lupus erythematosus
- mesenchymal stem cells
- immune response
- disease activity
- genome wide
- stem cells
- bone marrow
- oxidative stress
- end stage renal disease
- copy number
- umbilical cord
- ejection fraction
- newly diagnosed
- cell therapy
- chronic kidney disease
- rheumatoid arthritis
- prognostic factors
- peritoneal dialysis
- low dose
- dendritic cells
- high dose